Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With significant updates to EU cosmetic regulations anticipated for 2026, many non-EU brands are re-evaluating their choice of an EU Responsible Person (RP). Beyond simply fulfilling the legal require...
For a non-EU-based manufacturer of a medical device or Software as a Medical Device (SaMD) that processes the health data of EU residents, the appointment of a GDPR Article 27 Representative is a foun...
While many non-EU medical device manufacturers understand the basic requirement to appoint an EU Authorized Representative (AR) under the Medical Device Regulation (MDR), the full scope of this role i...
With the UK's regulatory framework for medical devices expected to see significant updates by 2026, many non-UK manufacturers are asking about the evolving role of the UK Responsible Person (UKRP). Wh...
For sponsors developing a novel Software as a Medical Device (SaMD) that falls into a Class II category, what is the practical role of Special Controls in a 510(k) submission, and what type of evidenc...
For non-EU based manufacturers of medical devices and Software as a Medical Device (SaMD), the requirement to appoint a GDPR Article 27 Representative is a familiar compliance obligation when processi...
As the Carbon Border Adjustment Mechanism (CBAM) transitions towards its definitive regime, non-EU importers of covered goods must secure representation for their reporting obligations. While many fir...
With the implementation of new mandatory facility registration and product listing requirements for cosmetics under the Modernization of Cosmetics Regulation Act (MoCRA), foreign establishments must n...
For non-EU medical device manufacturers, selecting an EU Authorised Representative (AR) under Regulation (EU) 2017/745 (MDR) is a critical compliance step with significant legal implications. Given th...
When developing Software as a Medical Device (SaMD) that incorporates an analytical algorithm, how do sponsors determine the appropriate regulatory requirements and necessary validation evidence? For ...
When a non-EU manufacturer seeks to appoint an EU Authorized Representative, particularly in light of emerging regulations like the Carbon Border Adjustment Mechanism (CBAM) which adds new responsibil...
With the FDA's Quality Management System Regulation (QMSR) now in effect as of February 2026, how should a foreign medical device manufacturer approach the process of selecting and qualifying an FDA U...
With evolving European regulatory expectations, particularly concerning post-market surveillance and vigilance reporting, how can medical device manufacturers, especially small to medium-sized enterpr...
What are the key distinctions between an EU Authorised Representative (AR) under the Medical Device Regulation (MDR) and a GDPR Article 27 Representative, and why might a medical device manufacturer n...
When non-EU manufacturers plan to enter the European market, they often encounter the need for local representation. However, it's crucial to distinguish between different regulatory requirements, suc...
As foreign medical device manufacturers navigate the transition to the FDA's new Quality Management System Regulation (QMSR) ahead of its February 2, 2026 effective date, how does this fundamental shi...
With evolving regulatory expectations for post-market surveillance and vigilance (PMSV) in the European Union, particularly concerning upcoming reporting updates, many medical device manufacturers are...
For non-EU/EEA companies manufacturing substances, preparing mixtures, or producing articles that will be placed on the European market, compliance with the REACH (Registration, Evaluation, Authorisat...
When evaluating the cost of appointing an EU Authorized Representative for the Carbon Border Adjustment Mechanism (CBAM), what are the key service components and risk factors that manufacturers should...
When non-EU manufacturers enter the European market, they often need an in-market entity to fulfill specific regulatory obligations. While roles like the EU Authorized Representative (AR) for medical ...